J. D. Wolchok

1.4k total citations
22 papers, 892 citations indexed

About

J. D. Wolchok is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, J. D. Wolchok has authored 22 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in J. D. Wolchok's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (6 papers). J. D. Wolchok is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (6 papers). J. D. Wolchok collaborates with scholars based in United States, Austria and Belgium. J. D. Wolchok's co-authors include Axel Hoos, Ramy Ibrahim, Rachel Humphrey, F. Stephen Hodi, Lloyd J. Old, Sylvia Janetzki, Brent A. Blumenstein, Abraham Anderson, Alexander Eggermont and Steven O’Day and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

J. D. Wolchok

21 papers receiving 868 citations

Peers

Countries citing papers authored by J. D. Wolchok

Since Specialization

Citations

This map shows the geographic impact of J. D. Wolchok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. D. Wolchok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. D. Wolchok more than expected).

Fields of papers citing papers by J. D. Wolchok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. D. Wolchok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. D. Wolchok. The network helps show where J. D. Wolchok may publish in the future.

Co-authorship network of co-authors of J. D. Wolchok

This figure shows the co-authorship network connecting the top 25 collaborators of J. D. Wolchok. A scholar is included among the top collaborators of J. D. Wolchok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. D. Wolchok. J. D. Wolchok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Poultry enteric inflammation model with dextran sodium sulfate mediated chemical induction and feed restriction in broilers 2015 ·Poultry Science ·V.A. Kuttappan, L. Berghman, (unknown), Juan D. Latorre, A. Menconi, J. D. Wolchok, A.D. Wolfenden, O.B. Faulkner, G I Tellez, Billy M. Hargis, L.R. Bielke	58
2	Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC) 2013 ·Cancer Research ·Adi Diab, (unknown), Christopher Comstock, Majid Maybody, Virgilio Sacchini, Jeremy C. Durack, (unknown), Jintao Yuan, Shekhar Patil, (unknown), (unknown), (unknown), Elizabeth A. Morris, Edi Brogi, Mark Morrow, J. D. Wolchok, (unknown), C. Hudis, Larry Norton, Heather L. McArthur	3
3	Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. 2011 ·Journal of Clinical Oncology ·Margaret K. Callahan, Aili Yang, (unknown), Ya Xu, Sumit K. Subudhi, (unknown), (unknown), (unknown), Deborah Kuk, K. Panageas, (unknown), James P. Allison, J. D. Wolchok	102
4	Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. 2011 ·Journal of Clinical Oncology ·Steven O’Day, Jeffrey S. Weber, J. D. Wolchok, Jon Richards, Paul Lorigan, David F. McDermott, Walter J. Urba, (unknown), Kevin N. Heller, (unknown), Axel Hauschild	25
5	Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. 2011 ·Journal of Clinical Oncology ·J. D. Wolchok, L. Thomas, (unknown), Steven O’Day, Jeffrey S. Weber, (unknown), Stephen Francis, Rebecca Ibrahim, Axel Hoos, Caroline Robert	11
6	Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. 2011 ·Journal of Clinical Oncology ·J. D. Wolchok, Linzi Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Stephen Francis, (unknown), Axel Hoos, Caroline Robert	17
7	Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) 2010 ·Annals of Oncology ·Paul Lorigan, Jeff Sosman, J.B.A.G. Haanen, Jose Lutzky, David Hogg, M. Gore, W J Urba, Veerle de Pril, (unknown), J. D. Wolchok	5
8	Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit of Dogs 2010 ·Journal of Veterinary Internal Medicine ·Christina Manley, Nicole F. Leibman, J. D. Wolchok, Isabelle Rivière, Shirley Bartido, D. Craft, Philip J. Bergman	49
9	Improved Endpoints for Cancer Immunotherapy Trials 2010 ·JNCI Journal of the National Cancer Institute ·Axel Hoos, Alexander Eggermont, Sylvia Janetzki, F. Stephen Hodi, Ramy Ibrahim, Abraham Anderson, Rachel Humphrey, Brent A. Blumenstein, Lloyd J. Old, J. D. Wolchok	371
10	Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. 2010 ·Journal of Clinical Oncology ·Mario Sznol, John D. Powderly, David C. Smith, Julie R. Brahmer, Charles G. Drake, David F. McDermott, Donald P. Lawrence, J. D. Wolchok, Suzanne L. Topalian, (unknown)	68
11	A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). 2010 ·Journal of Clinical Oncology ·Richard D. Carvajal, (unknown), John A. Thompson, Michael Gordon, Karl D. Lewis, Anne C. Pavlick, J. D. Wolchok, Floyd E. Fox, (unknown), A. Y. Bedikian	10
12	CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes. 2010 ·Journal of Clinical Oncology ·Allison L. Yang, (unknown), Brian Ginsberg, (unknown), (unknown), (unknown), (unknown), J. D. Wolchok	20
13	Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM) 2009 ·Journal of Clinical Oncology ·Patrick A. Ott, Richard D. Carvajal, Neeta Pandit‐Taskar, Achim A. Jungbluth, Eric W. Hoffman, Ralph Venhaus, (unknown), Lloyd J. Old, Anne C. Pavlick, J. D. Wolchok	5
14	9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 2009 ·European Journal of Cancer Supplements ·Dirk Schadendorf, J. D. Wolchok, Bart Neyns, Célèste Lebbé, Kaan Harmankaya, Claire F. Verschraegen, Kimberly J. Chin, (unknown), Axel Hoos, Michele Maio	5
15	Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials 2009 ·Journal of Clinical Oncology ·Jose Lutzky, J. D. Wolchok, Omid Hamid, Célèste Lebbé, Hubert Pehamberger, Gerald P. Linette, Veerle de Pril, Ramy Ibrahim, Axel Hoos, Steven O’Day	49
16	9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials 2009 ·European Journal of Cancer Supplements ·Michele Maio, (unknown), (unknown), Jessica A. Siegel, Axel Hoos, Rachel Humphrey, Steven O’Day, J. D. Wolchok, Jeffrey S. Weber, Kaan Harmankaya	6
17	Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment 2008 ·Journal of Clinical Oncology ·J. D. Wolchok, Ramy Ibrahim, (unknown), Michele Maio, Paola Queirolo, Kaan Harmankaya, Lisa Lundgren, Axel Hoos, Rachel Humphrey, Omid Hamid	22
18	Phase I trial of a PSMA DNA vaccine for patients(pts) with good risk renal cell carcinoma(RCC) 2008 ·Journal of Clinical Oncology ·(unknown), Robert J. Motzer, Melanie Jefferson, Polly D. Gregor, J. D. Wolchok, Matthew J. Czarny, Tracy Curley, A. Delacruz, Howard I. Scher	2
19	Cytokines in cytotherapy 2006 ·Cytotherapy ·(unknown), J. D. Wolchok	0
20	Vaccines for melanoma: translating basic immunology into new therapies 2001 ·The Lancet Oncology ·J. D. Wolchok, (unknown)	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact